查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1679344

肝癌藥物市場規模、佔有率、趨勢分析報告：按治療、類型、分銷管道、地區分類的細分趨勢，2025-2030 年

Liver Cancer Drug Market Size, Share & Trends Analysis Report By Therapy, By Type, By Distribution Channel, By Region, And Segment Forecasts 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格

肝癌藥物市場的成長與趨勢

根據Grand View Research, Inc.的最新報告，到2030年全球肝癌治療藥物市場規模預計將達到98.1億美元。

預計 2025 年至 2030 年間，市場複合年成長率將達到 17.9%。肝癌市場的成長主要受到新藥供應、強大研發線的存在以及社會意識的提高等因素的推動。肝癌患者數量的增加是由於不健康的生活方式和老年人口的增加。這對於肝癌藥物市場是利好。針對對 Nexavar 不耐受的患者開發二線治療方法預計將對肝癌領域產生重大影響。

肝癌是全球第五大常見癌症，佔癌症死亡人數的9.0%。據報道，2012年，全球新診斷的肝癌病例為782,451例，死於肝癌的人數為745,533人。原發性肝癌由於其高度侵襲性和較低的存活率，仍然是一個重大的公共衛生問題。肝細胞癌佔原發性肝癌的大多數（75-90％）。肝癌的許多顯著原因，包括肝炎感染和肝硬化，都是可以改變的，透過改變生活方式和接種肝炎疫苗等預防策略，有望降低肝癌的發病率和死亡率。

肝癌藥物市場報告重點

  • 由於針對與癌細胞生長和擴散相關的特定分子和途徑的高精度定位，標靶治療領域預計將在 2024 年佔據最大的市場收益佔有率，達到 53.1%。
  • 肝細胞癌 (HCC) 佔據肝癌藥物市場的主導地位，2024 年的收益佔有率為 38.2%。肝細胞癌是最常見的原發性肝癌類型。
  • 到 2024 年，醫院藥局將以 45.7% 的收益佔有率主導肝癌藥物市場。
  • 2024年北美肝癌藥物市佔率為38.7%。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第3章肝癌藥物市場變數、趨勢與範圍

  • 市場體系展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 商業環境分析
    • 產業分析 – 波特五力分析
    • PESTLE分析
    • 管道分析

第4章肝癌藥物市場：依治療類型分類的業務分析

  • 2024 年及 2030 年各療法市場佔有率
  • 治療細分儀表板
  • 2018 年至 2030 年按治療類型分類的市場規模、預測和趨勢分析
  • 標靶治療
  • 免疫療法
  • 化療
  • 其他

第5章肝癌藥物市場：按類型分類的業務分析

  • 2024 年及 2030 年各類型市場佔有率
  • 類型細分儀表板
  • 2018 年至 2030 年按類型分類的市場規模、預測與趨勢分析
  • 肝細胞癌
  • 膽管癌
  • 肝母細胞瘤
  • 其他

第 6 章 肝癌藥物市場：依通路分類的業務分析

  • 2024 年和 2030 年按分銷管道分類的市場佔有率
  • 分銷通路細分儀表板
  • 2018 年至 2030 年分銷通路市場規模、預測與趨勢分析
  • 醫院藥房
  • 零售藥局
  • 網路藥局

第 7 章肝癌藥物市場：區域、估計和趨勢分析

  • 2024 年及 2030 年區域市場佔有率分析
  • 區域市場儀表板
  • 2018-2030年市場規模、預測趨勢分析
  • 北美洲
    • 2018-2030年各國情況
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 按國家/地區，2018 年至 2030 年
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 2018-2030年各國情況
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 按國家/地區，2018 年至 2030 年
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 2018-2030年各國情況
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章 競爭格局

  • 參與者概述
  • 企業市場分析
  • 公司分類
  • 戰略地圖
  • 公司簡介/上市公司
    • Exelixis, Inc.
    • Merck KGaA
    • Eisai Co., Ltd.
    • Bristol-Myers Squibb Company
    • Thermo Fisher Scientific Inc.
    • Pfizer Inc.
    • Eli Lilly and Company
    • F. Hoffmann-La Roche Ltd
    • Novartis AG
    • Bayer AG
Product Code: GVR-2-68038-513-7

Liver Cancer Drug Market Growth & Trends:

The global liver cancer drug market size is anticipated to reach USD 9.81 billion by 2030, according to a new report by Grand View Research, Inc. The market is projected to grow at a CAGR of 17.9% from 2025 to 2030. The growth of liver cancer market is largely driven by factors such as availability of novel drugs, presence of strong pipeline, and rising public awareness. Widening base of liver cancer patients can be attributed to unhealthy lifestyles and growing geriatric population. This, in turn, is working in favor of the liver cancer therapeutics market. Therapeutic development in second-line setting for Nexavar-intolerant patients is estimated to have a major impact in the HCC space.

Liver cancer is the fifth most prevalent cancer worldwide and accounts for 9.0% of all cancer deaths. In 2012, 782,451 new cases of liver cancer were diagnosed, and 745,533 deaths were reported due to liver cancer. Primary liver cancer remains an important public health issue due to its extremely aggressive nature and poor survival rate. Hepatocellular carcinomas (HCCs) represents the majority (75-90%) of primary liver cancers. A noteworthy number of etiological factors of liver cancer, including hepatitis infection and cirrhosis, can be modified and present a strong prospect to reduce its incidence and mortality by preventive strategies such as lifestyle modification and hepatitis immunization.

Liver Cancer Drug Market Report Highlights:

  • The targeted therapy segment held the largest market revenue share of 53.1% in 2024 due to its precision in targeting specific molecules or pathways involved in the growth and spread of cancer cells.
  • Hepatocellular Carcinoma (HCC) dominated the liver cancer drug market with a 38.2% revenue share in 2024. HCC Is the most common type of primary liver cancer.
  • Hospital pharmacy dominated the liver cancer drug market with a revenue share of 45.7% in 2024.
  • North America liver cancer drug market held a revenue share of 38.7% in 2024.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Therapy
    • 1.2.2. Type
    • 1.2.3. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Liver Cancer Drug Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis

Chapter 4. Liver Cancer Drug Market: Therapy Business Analysis

  • 4.1. Therapy Market Share, 2024 & 2030
  • 4.2. Therapy Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Therapy, 2018 to 2030 (USD Million)
  • 4.4. Targeted Therapy
    • 4.4.1. Targeted Therapy Market, 2018 - 2030 (USD Million)
  • 4.5. Immunotherapy
    • 4.5.1. Immunotherapy Market, 2018 - 2030 (USD Million)
  • 4.6. Chemotherapy
    • 4.6.1. Chemotherapy Market, 2018 - 2030 (USD Million)
  • 4.7. Others
    • 4.7.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. Liver Cancer Drug Market: Type Business Analysis

  • 5.1. Type Market Share, 2024 & 2030
  • 5.2. Type Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Type, 2018 to 2030 (USD Million)
  • 5.4. Hepatocellular Carcinoma
    • 5.4.1. Hepatocellular Carcinoma Market, 2018 - 2030 (USD Million)
  • 5.5. Cholangio Carcinoma
    • 5.5.1. Cholangio Carcinoma Market, 2018 - 2030 (USD Million)
  • 5.6. Hepatoblastoma
    • 5.6.1. Hepatoblastoma Market, 2018 - 2030 (USD Million)
  • 5.7. Others
    • 5.7.1. Others Market, 2018 - 2030 (USD Million)

Chapter 6. Liver Cancer Drug Market: Distribution Channel Business Analysis

  • 6.1. Distribution Channel Market Share, 2024 & 2030
  • 6.2. Distribution Channel Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
  • 6.4. Hospital Pharmacies
    • 6.4.1. Hospital Pharmacies Market, 2018 - 2030 (USD Million)
  • 6.5. Retail Pharmacies
    • 6.5.1. Retail Pharmacies Market, 2018 - 2030 (USD Million)
  • 6.6. Online Pharmacies
    • 6.6.1. Online Pharmacies Market, 2018 - 2030 (USD Million)

Chapter 7. Liver Cancer Drug Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2024 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.4. North America
    • 7.4.1. North America Liver Cancer Drug Market Estimates and Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Regulatory Framework
      • 7.4.2.3. Competitive Insights
      • 7.4.2.4. U.S. Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Regulatory Framework
      • 7.4.3.3. Competitive Insights
      • 7.4.3.4. Canada Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. Mexico
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Regulatory Framework
      • 7.4.4.3. Competitive Insights
      • 7.4.4.4. Mexico Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Europe
    • 7.5.1. Europe Liver Cancer Drug Market Estimates and Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.5.2. Germany
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Regulatory Framework
      • 7.5.2.3. Competitive Insights
      • 7.5.2.4. Germany Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. UK
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Regulatory Framework
      • 7.5.3.3. Competitive Insights
      • 7.5.3.4. UK Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.4. France
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Regulatory Framework
      • 7.5.4.3. Competitive Insights
      • 7.5.4.4. France Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.5. Italy
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Regulatory Framework
      • 7.5.5.3. Competitive Insights
      • 7.5.5.4. Italy Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.6. Spain
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Regulatory Framework
      • 7.5.6.3. Competitive Insights
      • 7.5.6.4. Spain Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.7. Denmark
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Regulatory Framework
      • 7.5.7.3. Competitive Insights
      • 7.5.7.4. Denmark Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.8. Sweden
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Regulatory Framework
      • 7.5.8.3. Competitive Insights
      • 7.5.8.4. Sweden Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.9. Norway
      • 7.5.9.1. Key Country Dynamics
      • 7.5.9.2. Regulatory Framework
      • 7.5.9.3. Competitive Insights
      • 7.5.9.4. Norway Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Asia Pacific Liver Cancer Drug Market Estimates and Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.6.2. Japan
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Regulatory Framework
      • 7.6.2.3. Competitive Insights
      • 7.6.2.4. Japan Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. China
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Regulatory Framework
      • 7.6.3.3. Competitive Insights
      • 7.6.3.4. China Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. India
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Regulatory Framework
      • 7.6.4.3. Competitive Insights
      • 7.6.4.4. India Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.5. Australia
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Regulatory Framework
      • 7.6.5.3. Competitive Insights
      • 7.6.5.4. Australia Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.6. South Korea
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Regulatory Framework
      • 7.6.6.3. Competitive Insights
      • 7.6.6.4. South Korea Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.7. Thailand
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. Regulatory Framework
      • 7.6.7.3. Competitive Insights
      • 7.6.7.4. Thailand Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Latin America Liver Cancer Drug Market Estimates and Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.7.2. Brazil
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Regulatory Framework
      • 7.7.2.3. Competitive Insights
      • 7.7.2.4. Brazil Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.7.3. Argentina
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Regulatory Framework
      • 7.7.3.3. Competitive Insights
      • 7.7.3.4. Argentina Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8. MEA
    • 7.8.1. MEA Liver Cancer Drug Market Estimates and Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.8.2. South Africa
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Regulatory Framework
      • 7.8.2.3. Competitive Insights
      • 7.8.2.4. South Africa Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Regulatory Framework
      • 7.8.3.3. Competitive Insights
      • 7.8.3.4. Saudi Arabia Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.8.4. UAE
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Regulatory Framework
      • 7.8.4.3. Competitive Insights
      • 7.8.4.4. UAE Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.8.5. Kuwait
      • 7.8.5.1. Key Country Dynamics
      • 7.8.5.2. Regulatory Framework
      • 7.8.5.3. Competitive Insights
      • 7.8.5.4. Kuwait Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Participant Overview
  • 8.2. Company Market Position Analysis
  • 8.3. Company Categorization
  • 8.4. Strategy Mapping
  • 8.5. Company Profiles/Listing
    • 8.5.1. Exelixis, Inc.
      • 8.5.1.1. Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Product Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. Merck KGaA
      • 8.5.2.1. Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Product Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. Eisai Co., Ltd.
      • 8.5.3.1. Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Product Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. Bristol-Myers Squibb Company
      • 8.5.4.1. Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Product Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. Thermo Fisher Scientific Inc.
      • 8.5.5.1. Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Product Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. Pfizer Inc.
      • 8.5.6.1. Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Product Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. Eli Lilly and Company
      • 8.5.7.1. Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Product Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. F. Hoffmann-La Roche Ltd
      • 8.5.8.1. Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Product Benchmarking
      • 8.5.8.4. Strategic Initiatives
    • 8.5.9. Novartis AG
      • 8.5.9.1. Overview
      • 8.5.9.2. Financial Performance
      • 8.5.9.3. Product Benchmarking
      • 8.5.9.4. Strategic Initiatives
    • 8.5.10. Bayer AG
      • 8.5.10.1. Overview
      • 8.5.10.2. Financial Performance
      • 8.5.10.3. Product Benchmarking
      • 8.5.10.4. Strategic Initiatives

List of Tables

  • Table 1 List Of Secondary Sources
  • Table 2 List Of Abbreviations
  • Table 3 Global Liver Cancer Drug Market, By Region, 2018 - 2030 (USD Million)
  • Table 4 Global Liver Cancer Drug Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 5 Global Liver Cancer Drug Market, By Type, 2018 - 2030 (USD Million)
  • Table 6 Global Liver Cancer Drug Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 7 North America Liver Cancer Drug Market, By Country, 2018 - 2030 (USD Million)
  • Table 8 North America Liver Cancer Drug Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 9 North America Liver Cancer Drug Market, By Type, 2018 - 2030 (USD Million)
  • Table 10 North America Liver Cancer Drug Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 11 U.S. Liver Cancer Drug Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 12 U.S. Liver Cancer Drug Market, By Type, 2018 - 2030 (USD Million)
  • Table 13 U.S. Liver Cancer Drug Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 14 Canada Liver Cancer Drug Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 15 Canada Liver Cancer Drug Market, By Type, 2018 - 2030 (USD Million)
  • Table 16 Canada Liver Cancer Drug Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 17 Mexico Liver Cancer Drug Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 18 Mexico Liver Cancer Drug Market, By Type, 2018 - 2030 (USD Million)
  • Table 19 Mexico Liver Cancer Drug Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 20 Europe Liver Cancer Drug Market, By Country, 2018 - 2030 (USD Million)
  • Table 21 Europe Liver Cancer Drug Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 22 Europe Liver Cancer Drug Market, By Type, 2018 - 2030 (USD Million)
  • Table 23 Europe Liver Cancer Drug Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 24 Germany Liver Cancer Drug Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 25 Germany Liver Cancer Drug Market, By Type, 2018 - 2030 (USD Million)
  • Table 26 Germany Liver Cancer Drug Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 27 UK Liver Cancer Drug Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 28 UK Liver Cancer Drug Market, By Type, 2018 - 2030 (USD Million)
  • Table 29 UK Liver Cancer Drug Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 30 France Liver Cancer Drug Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 31 France Liver Cancer Drug Market, By Type, 2018 - 2030 (USD Million)
  • Table 32 France Liver Cancer Drug Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 33 Italy Liver Cancer Drug Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 34 Italy Liver Cancer Drug Market, By Type, 2018 - 2030 (USD Million)
  • Table 35 Italy Liver Cancer Drug Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 36 Spain Liver Cancer Drug Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 37 Spain Liver Cancer Drug Market, By Type, 2018 - 2030 (USD Million)
  • Table 38 Spain Liver Cancer Drug Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 39 Denmark Liver Cancer Drug Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 40 Denmark Liver Cancer Drug Market, By Type, 2018 - 2030 (USD Million)
  • Table 41 Denmark Liver Cancer Drug Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 42 Sweden Liver Cancer Drug Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 43 Sweden Liver Cancer Drug Market, By Type, 2018 - 2030 (USD Million)
  • Table 44 Sweden Liver Cancer Drug Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 45 Norway Liver Cancer Drug Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 46 Norway Liver Cancer Drug Market, By Type, 2018 - 2030 (USD Million)
  • Table 47 Norway Liver Cancer Drug Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 48 Asia Pacific Liver Cancer Drug Market, By Country, 2018 - 2030 (USD Million)
  • Table 49 Asia Pacific Liver Cancer Drug Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 50 Asia Pacific Liver Cancer Drug Market, By Type, 2018 - 2030 (USD Million)
  • Table 51 Asia Pacific Liver Cancer Drug Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 52 Japan Liver Cancer Drug Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 53 Japan Liver Cancer Drug Market, By Type, 2018 - 2030 (USD Million)
  • Table 54 Japan Liver Cancer Drug Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 55 China Liver Cancer Drug Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 56 China Liver Cancer Drug Market, By Type, 2018 - 2030 (USD Million)
  • Table 57 China Liver Cancer Drug Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 58 India Liver Cancer Drug Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 59 India Liver Cancer Drug Market, By Type, 2018 - 2030 (USD Million)
  • Table 60 India Liver Cancer Drug Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 61 Australia Liver Cancer Drug Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 62 Australia Liver Cancer Drug Market, By Type, 2018 - 2030 (USD Million)
  • Table 63 Australia Liver Cancer Drug Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 64 South Korea Liver Cancer Drug Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 65 South Korea Liver Cancer Drug Market, By Type, 2018 - 2030 (USD Million)
  • Table 66 South Korea Liver Cancer Drug Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 67 Thailand Liver Cancer Drug Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 68 Thailand Liver Cancer Drug Market, By Type, 2018 - 2030 (USD Million)
  • Table 69 Thailand Liver Cancer Drug Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 70 Latin America Liver Cancer Drug Market, By Country, 2018 - 2030 (USD Million)
  • Table 71 Latin America Liver Cancer Drug Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 72 Latin America Liver Cancer Drug Market, By Type, 2018 - 2030 (USD Million)
  • Table 73 Latin America Liver Cancer Drug Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 74 Brazil Liver Cancer Drug Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 75 Brazil Liver Cancer Drug Market, By Type, 2018 - 2030 (USD Million)
  • Table 76 Brazil Liver Cancer Drug Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 77 Argentina Liver Cancer Drug Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 78 Argentina Liver Cancer Drug Market, By Type, 2018 - 2030 (USD Million)
  • Table 79 Argentina Liver Cancer Drug Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 80 Middle East & Africa Liver Cancer Drug Market, By Country, 2018 - 2030 (USD Million)
  • Table 81 Middle East & Africa Liver Cancer Drug Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 82 Middle East & Africa Liver Cancer Drug Market, By Type, 2018 - 2030 (USD Million)
  • Table 83 Middle East & Africa Liver Cancer Drug Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 84 South Africa Liver Cancer Drug Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 85 South Africa Liver Cancer Drug Market, By Type, 2018 - 2030 (USD Million)
  • Table 86 South Africa Liver Cancer Drug Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 87 Saudi Arabia Liver Cancer Drug Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 88 Saudi Arabia Liver Cancer Drug Market, By Type, 2018 - 2030 (USD Million)
  • Table 89 Saudi Arabia Liver Cancer Drug Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 90 UAE Liver Cancer Drug Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 91 UAE Liver Cancer Drug Market, By Type, 2018 - 2030 (USD Million)
  • Table 92 UAE Liver Cancer Drug Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 93 Kuwait Liver Cancer Drug Market, By Therapy, 2018 - 2030 (USD Million)
  • Table 94 Kuwait Liver Cancer Drug Market, By Type, 2018 - 2030 (USD Million)
  • Table 95 Kuwait Liver Cancer Drug Market, By Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Liver Cancer Drug Market Segmentation
  • Fig. 2 Market Research Process
  • Fig. 3 Data Triangulation Techniques
  • Fig. 4 Primary Research Pattern
  • Fig. 5 Market Research Approaches
  • Fig. 6 Value-Chain-Based Sizing & Forecasting
  • Fig. 7 Market Formulation & Validation
  • Fig. 8 Market Snapshot
  • Fig. 9 Therapy and Type Outlook (USD Million)
  • Fig. 10 Distribution Channel Outlook (USD Million)
  • Fig. 11 Competitive Landscape
  • Fig. 12 Liver Cancer Drug Market Dynamics
  • Fig. 13 Liver Cancer Drug Market: Porter's Five Forces Analysis
  • Fig. 14 Liver Cancer Drug Market: PESTLE Analysis
  • Fig. 15 Liver Cancer Drug Market: Therapy Segment Dashboard
  • Fig. 16 Liver Cancer Drug Market: Therapy Market Share Analysis, 2024 & 2030
  • Fig. 17 Targeted Therapy Market, 2018 - 2030 (USD Million)
  • Fig. 18 Immunotherapy Market, 2018 - 2030 (USD Million)
  • Fig. 19 Chemotherapy Market, 2018 - 2030 (USD Million)
  • Fig. 20 Others Market, 2018 - 2030 (USD Million)
  • Fig. 21 Liver Cancer Drug Market: Type Segment Dashboard
  • Fig. 22 Liver Cancer Drug Market: Type Market Share Analysis, 2024 & 2030
  • Fig. 23 Hepatocellular Carcinoma Market, 2018 - 2030 (USD Million)
  • Fig. 24 Cholangio Carcinoma Market, 2018 - 2030 (USD Million)
  • Fig. 25 Hepatoblastoma Market, 2018 - 2030 (USD Million)
  • Fig. 26 Others Market, 2018 - 2030 (USD Million)
  • Fig. 27 Liver Cancer Drug Market: Distribution Channel Segment Dashboard
  • Fig. 28 Liver Cancer Drug Market: Distribution Channel Market Share Analysis, 2024 & 2030
  • Fig. 29 Hospital Pharmacies Market, 2018 - 2030 (USD Million)
  • Fig. 30 Retail Pharmacies Market, 2018 - 2030 (USD Million)
  • Fig. 31 Online Pharmacies Market, 2018 - 2030 (USD Million)
  • Fig. 32 Liver Cancer Drug Market Revenue, By Region
  • Fig. 33 Regional Marketplace: Key Takeaways
  • Fig. 34 Regional Marketplace: Key Takeaways
  • Fig. 35 North America Liver Cancer Drug Market, 2018 - 2030 (USD Million)
  • Fig. 36 U.S. Country Dynamics
  • Fig. 37 U.S. Liver Cancer Drug Market, 2018 - 2030 (USD Million)
  • Fig. 38 Canada Country Dynamics
  • Fig. 39 Canada Liver Cancer Drug Market, 2018 - 2030 (USD Million)
  • Fig. 40 Mexico Country Dynamics
  • Fig. 41 Mexico Liver Cancer Drug Market, 2018 - 2030 (USD Million)
  • Fig. 42 Europe Liver Cancer Drug Market, 2018 - 2030 (USD Million)
  • Fig. 43 Germany Country Dynamics
  • Fig. 44 Germany Liver Cancer Drug Market, 2018 - 2030 (USD Million)
  • Fig. 45 UK Country Dynamics
  • Fig. 46 UK Liver Cancer Drug Market, 2018 - 2030 (USD Million)
  • Fig. 47 France Country Dynamics
  • Fig. 48 France Liver Cancer Drug Market, 2018 - 2030 (USD Million)
  • Fig. 49 Italy Country Dynamics
  • Fig. 50 Italy Liver Cancer Drug Market, 2018 - 2030 (USD Million)
  • Fig. 51 Spain Country Dynamics
  • Fig. 52 Spain Liver Cancer Drug Market, 2018 - 2030 (USD Million)
  • Fig. 53 Norway Country Dynamics
  • Fig. 54 Norway Liver Cancer Drug Market, 2018 - 2030 (USD Million)
  • Fig. 55 Sweden Country Dynamics
  • Fig. 56 Sweden Liver Cancer Drug Market, 2018 - 2030 (USD Million)
  • Fig. 57 Denmark Country Dynamics
  • Fig. 58 Denmark Liver Cancer Drug Market, 2018 - 2030 (USD Million)
  • Fig. 59 Asia Pacific Liver Cancer Drug Market, 2018 - 2030 (USD Million)
  • Fig. 60 Japan Country Dynamics
  • Fig. 61 Japan Liver Cancer Drug Market, 2018 - 2030 (USD Million)
  • Fig. 62 China Country Dynamics
  • Fig. 63 China Liver Cancer Drug Market, 2018 - 2030 (USD Million)
  • Fig. 64 India Country Dynamics
  • Fig. 65 India Liver Cancer Drug Market, 2018 - 2030 (USD Million)
  • Fig. 66 Australia Country Dynamics
  • Fig. 67 Australia Liver Cancer Drug Market, 2018 - 2030 (USD Million)
  • Fig. 68 South Korea Country Dynamics
  • Fig. 69 South Korea Liver Cancer Drug Market, 2018 - 2030 (USD Million)
  • Fig. 70 Thailand Country Dynamics
  • Fig. 71 Thailand Liver Cancer Drug Market, 2018 - 2030 (USD Million)
  • Fig. 72 Latin America Liver Cancer Drug Market, 2018 - 2030 (USD Million)
  • Fig. 73 Brazil Country Dynamics
  • Fig. 74 Brazil Liver Cancer Drug Market, 2018 - 2030 (USD Million)
  • Fig. 75 Argentina Country Dynamics
  • Fig. 76 Argentina Liver Cancer Drug Market, 2018 - 2030 (USD Million)
  • Fig. 77 MEA Liver Cancer Drug Market, 2018 - 2030 (USD Million)
  • Fig. 78 South Africa Country Dynamics
  • Fig. 79 South Africa Liver Cancer Drug Market, 2018 - 2030 (USD Million)
  • Fig. 80 Saudi Arabia Country Dynamics
  • Fig. 81 Saudi Arabia Liver Cancer Drug Market, 2018 - 2030 (USD Million)
  • Fig. 82 UAE Country Dynamics
  • Fig. 83 UAE Liver Cancer Drug Market, 2018 - 2030 (USD Million)
  • Fig. 84 Kuwait Country Dynamics
  • Fig. 85 Kuwait Liver Cancer Drug Market, 2018 - 2030 (USD Million)
  • Fig. 86 Company Categorization
  • Fig. 87 Company Market Position Analysis
  • Fig. 88 Strategic Framework